An Institute for Research on Public Policy study says discontinuing seniors’ drug benefits is a step in the wrong direction. Provinces should instead provide full and universal coverage of prescription drug costs for all and finance the new programs through personal income taxes.
Providers and pharmacies come together around mutual goals, bringing new opportunities for benefits plan sponsors.
AbbVie's board of directors is recommending that its shareholders vote against the deal to buy Shire Pharmaceuticals.
AbbVie is reconsidering its acquisition of Shire Pharmaceuticals after the United States Treasury Department announced it would crack down on tax inversions.
U.S.-based AbbVie has reached a deal to acquire its European rival, Shire Pharmaceuticals, for about £32 billion ($58.6 billion).
Despite claims from critics, incremental innovations by drug companies provide great value for doctors and patients, according to a study.
The world of pharmaceuticals is changing. New, more effective medications are replacing older ones, more biologic treatments are being developed, advances are being made in treating catastrophic illnesses, and drug patents are expiring resulting in more and more generic alternatives becoming available. Canada’s population is changing, too. Our aging population means an increased demand for […]
Drug plan costs are an ongoing concern for Canadian employers. Benefits Canada’s Face to Face Drug Plan Management Forum in Vancouver shows how plan sponsors out west are managing them.
The Ordre des pharmaciens du Québec is looking at ways to ban drug loyalty cards in the province.
There is overwhelming evidence of the impact of wealth on people’s health, according to a report.